Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
|Number of pages||3|
|Journal||British Journal of Cancer|
|Publication status||Published - 1995|
- Advanced breast cancer
- Second-line treatment
ASJC Scopus subject areas
- Cancer Research